During the last decade, the aminoglycoside antibiotics have become the mainstay of therapy for severe gram-negative bacillary infections (21, 24, 34) . Resistance to gentamicin and tobramycin in gram-negative bacilli and staphylococci is a growing clinical problem (6, 7, 14, 15, 21, 24, 28, 34) . A common mechanism of aminoglycoside resistance is through plasmid-specified enzymes (5, (7) (8) (9) 22) (8, 9) .
Amikacin is a derivative of kanamycin-A acetylated with the L-(-)-y-amino-a-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety (18) . The resulting molecule has antimicrobial activity against many bacteria resistant to gentamicin and tobramycin, since enzymatic inactivation of amikacin occurs primarily at the 6' amino position in enteric bacteria (26, 28) . Although aminoglycoside acetyltransferase AAC(6')-1 is the enzyme most commonly associated with enzyme-mediated amikacin resistance, other enzymes for which amikacin serves as a substrate include APH(2") and ANT(4') (9, 27) . Reports of outbreaks due to amikacin-resistant organisms have been sparse and have seldom elucidated the mechanism of amikacin resistance (15, 24, 33 (3, 27) . Test aminoglycosides included paromomycin, lividomycin, netilmicin, and butirosin, in addition to amikacin, gentamicin, tobramycin, and kanamycin. The substrate profile obtained with these eight agents was generally adequate to identify accurately the specific enzymes present in the crude cellular preparations under study. The amount of radioactivity specifically associated with each test aminoglycoside was estimated by use of a Tri-Carb liquid scintillation spectrometer (Packard Instrument Co., Downers Grove, Ill.).
Conjugation and curing procedures. ARSM were mated with Escherichia coli C as previously described (16) . Filter matings to detect plasmids with low transfer frequencies (23) were also performed at 37 and 22°C (12) . Transconjugants were selected on plates containing 10 1Lg of gentamicin per ml and also on plates containing 20 ,ug of amikacin per ml. Transfer frequency was considered the total number of transconjugants divided by the total number of donor cells at 24 h.
Plasmid-curing experiments were performed by incubation of bacteria in the dark at 37°C for 24 h in nutrient broth (Difco) containing ethidium bromide (80 to 250 ,ug/ml), acridine orange (250 to 500 ,ug/ml), and novobiocin (4 to 500 ,ug/ml). Serial dilutions were plated to Trypticase soy agar (BBL Microbiology Systems, Cockeysville, Md.), and individual colonies were picked to Mueller-Hinton agar (Difco) containing gentamicin (20 t.g/ml) or to nutrient agar (Difco) containing mercuric chloride (40 jig/ml).
DNA procedures. Cleared lysates were prepared as previously described (16) and also by the alkaline lysis method (17) and electrophoresed in 0.7% agarose at 50 mA for 3 h. Cleared lysates of S. marcescens 399, 431, and 01 were also subjected to cesium chloride-ethidium bromide density centrifugation and electrophoresed as described to detect any additional plasmids. Restriction endonuclease analysis using HaeII (Bethesda Research Laboratories, Gaithersburg, Md.) was performed on plasmid DNA from E. coli transconjugant which was purified by ethidium bromide-cesium chloride density gradient centrifugation (16 RESULTS From 1977 to 1980, aminoglycoside-resistant S. marcescens was endemic at Medical University Hospital in Charleston. Over 90% of these strains contained a 41-megadalton (Md) plasmid specifying gentamicin and tobramycin resistance as described in detail elsewhere (15) . Only 4% of all aminoglycoside-resistant S. marcescens isolates during this time were amikacin resistant. On the other hand, the predominant endemic S. marcescens at the Chicago and Columbia, S.C., hospitals were amikacin resistant. Of the four ARSM from Charleston, two contained a conjugative 40-Md plasmid and two contained a conjugative 56-Md plasmid (Fig. 1) . Both the 40-and 56-Md plasmids were transferred to E. coli C at a frequency of 10-2 to 10-3 at 24 h. Transconjugants were resistant to ampicillin, carbenicillin, gentamicin, kanamycin, sisomicin, sulfonamide, and tobramycin. Additional resistance to mercury (MIC 2 40 ,ug/ml) was transferred by the 56-Md plasmid. Restriction endonuclease digest of the 56-and 40-Md plasmids revealed minimal similarity with each other or with the 41-Md ARSM containing the 56-Md plasmid produced both AAC(6') and ANT(2") ( Table 1 ). The transconjugant E. coli(pJFJ399) containing the 56-Md plasmid produced only ANT(2") and was susceptible to amikacin. S. marcescens 399 cured by exposure to ethidium bromide contained no plasmids on agarose gel electrophoresis, produced only AAC(6'), and was also resistant to amikacin. The other representative Charleston strain, S. marcescens 431, which contained a 40-Md plasmid, elaborated not only AAC(6') and ANT(2") but also APH(3')-1. Only the ANT(2") was transferable (Table 1) .
Ten ARSM from Chicago uniformly contained a single conjugative 100-Md plasmid which coded for gentamicin and tobramycin resistance. The parent strain elaborated both an AAC(6')-1 and an AAC(3)-11, whereas the transconjugant elaborated only AAC(3)-11. The Columbia, S.C., ARSM contained a conjugative 53-Md plasmid which elaborated an ANT(2") or an ANT(2') plus an APH(3')-11. A single ARSM strain from Columbia, SM083, which was amikacin and tobramycin resistant but gentamicin susceptible, contained no plasmids and elaborated a single enzyme, AAC(6')-1. Multiple attempts to cure ARSM other than SM399 of plasmids were unsuccessful.
Substrate profiles for selected ARSM differed primarily in their activity against gentamicin, which may explain why some susceptibility testing to gentamicin ranged from susceptible to moderately resistant (Table 2) .
ARSM from these different cities were alike in three regards: (i) amikacin resistance was not transferable; (ii) selected donor strains all produced an AAC(6') with similar substrate profiles which was not produced by amikacin-susceptible, gentamicin-resistant, tobramycin-resistant transconjugants; and (iii) all but one ARSM contained a conjugative plasmid which coded for at least one other aminoglycoside-modifying en- zyme. These data for ARSM are consistent with a chromosomal site for AAC(6') production. DISCUSSION ARSM at Medical University Hospital emerged during a prolonged outbreak of a multiresistant S. marcescens containing a conjugative 41-Md plasmid (15) . The ARSM of a different serotype from the outbreak strain not only contained different conjugative plasmids specifying resistance to gentamicin, tobramycin, and kanamycin via an ANT(2") enzyme but also elaborated a nontransferable AAC(6') which produced additional resistance to amikacin but not gentamicin. Since all aminoglycoside-resistant Serratia were monitored during this time at Medical University Hospital, we conclude that there was negligible spread of the ARSM. Furthermore, there was minimal DNA similarity between the more prominent 41-Md plasmid and the plasmids (40 and 56 Md) isolated from the ARSM, suggesting that these plasmids were of different origin. Since the ARSM and the outbreak Serratia were of different serotypes, it is not possible to say if the decreased spread of the amikacin resistant strain was host or plasmid related.
Other workers have described aminoglycoside-modifying enzymes which could not be transferred by conjugation or transformation of plasmid DNA: APH(3') and AAC(6') in Acinetobacter calcoaceticus (25) ; AAC(6') in Pseudomonas aeruginosa and S. marcescens (32); and AAC(2') in Providencia (Proteus) retgerii (20) . Recently, Kayser et al., working with Staphylococcus aureus, have presented good evidence for a chromosomal site of aminoglycoside-modifying enzyme production (19) . They reported two R-plasmid-containing S. aureus isolates with chromosomal production of APH(3') specifying kanamycin resistance in one strain and APH(2") and AAC(6') specifying kanamycin, gentamicin, and tobramycin resistance in the second. Attempts to cure the aforementioned resistant gram-negative bacteria of their plasmids in order to demonstrate concomitant loss of aminoglycoside-modifying enzyme production have been unsuccessful to date. Indeed, after many attempts in several organisms using three curing agents, we were successful in curing only one S. marcescens of its plasmidrelated enzyme activity.
The presence of chromosomal genes specifying aminoglycoside resistance in enteric bacteria raises three major considerations. First, resistance to amikacin may be mediated by a transposable segment. Over one-third of reported transposons specify aminoglycoside resistance, most commonly gentamicin, kanamycin, neomycin, and streptomycin (4) . In several instances, kanamycin, neomycin, and streptomycin resistance transpose to the E. coli chromosome (4), but this has not been reported for amikacin. Second, a conjugative plasmid could be integrated into the chromosome as has been described for Haemophilus influenzae and H. parainfluenzae (30) . We were unable to demonstrate any transfer of amikacin resistance by plasmidless strains, using filter matings at various temperatures. It reamins for us to attempt mobilization of amikacin resistance. Recently, a naturally occurring transmissible plasmid, pAV1, in A. calcoaceticus has been shown to mobilize nontransmissible neomycin resistance (13) . Third, a chromosomal locus could be repressed in susceptible strains only to be derepressed under selective environmental conditions. Grassi has shown that in E. coli R112, which has a plasmid-mediated APH(3')-1, exposure to subminimal inhibitory concentration of gentamicin results in the production of an AAC(2') after 20 subcultures (10).
